AIkido Pharma Inc (AIKI)

[Viewmont]

Yup! https://www.benzinga.com/news/20/07/16576098/why-alkido-pharmas-stock-is-trading-higher-today

[Viewmont]

We need to hear from company, finalized approved products. Hopefully soon!

[Viewmont]

Hydroxychloroquine. What about it?

[mick]

$AIKI READING INFO http://www.Benzinga.com

RE;
Options Trade Ideas from Benzinga
In this market, there's never been a better time to profit with options. Get Benzinga Options: Starter Edition to follow Nic Chahine's high-conviction options trades. Click here to subscribe.

AIkido Pharma is a U.S.-based biotechnology company. The company is engaged in the development of small-molecule anti-cancer therapeutics. The company's drug portfolio includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL).

Aikido Pharma's stock was trading up 5.77% at 92 cents on Thursday during the time of publication. The stock has a 52-week high of $5.52 and a 52-week low of 48 cents.

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

[mick]

$AIKI , THANK YOU FER INFO. YA HAVE DA LINK ?????

RE;
Aikido Pharma Announces Key Progress In Computational Approaches To Identify Virus Treatments, Including Coronavirus
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
July 09, 2020 1:32pm 1 min read Comments

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

[mick]

Alkido Pharma Inc (AIKI)
0.8529 ? 0.0132 (1.57%)
Volume: 1,062,244 @07/15/20 1:08:58 PM EDT
Bid Ask Day's Range
0.8501 0.8529 0.8267 - 0.853
AIKI Detailed Quote

[mick]

$AIKI would know name of dat drug ????? hydo something

[Viewmont]

From last week. https://www.benzinga.com/news/20/07/16576098/why-alkido-pharmas-stock-is-trading-higher-today

[Viewmont]

Aikido Pharma Announces Key Progress In Computational Approaches To Identify Virus Treatments, Including Coronavirus
Benzinga Newsdesk , Benzinga Staff Writer FOLLOW
July 09, 2020 1:32pm 1 min read Comments
This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

[mick]

$AIKI IS HOTH ah spinoff from $AIKI ????? WHAT WAS SPINOFF SHARES ?????

RE;
https://www.prnewswire.com/news-releases/aikido-pharma-inc-sets-record-date-for-hoth-distribution-301043157.html

https://www.streetinsider.com/PRNewswire/Hoth+Therapeutics%2C+Inc.%2C+Voltron+Therapeutics%2C+Inc.%2C+%26amp%3B+HaloVax+Announce+Selection+of+the+First+of+Two+Sets+of+Virus+Targeting+Peptides+for+Animal+Testing+in+the+Development+of+a+COVID-19+Vaccine/16782289.html

[Viewmont]

https://www.prnewswire.com/news-releases/aikido-pharma-inc-sets-record-date-for-hoth-distribution-301043157.html

https://www.streetinsider.com/PRNewswire/Hoth+Therapeutics%2C+Inc.%2C+Voltron+Therapeutics%2C+Inc.%2C+%26amp%3B+HaloVax+Announce+Selection+of+the+First+of+Two+Sets+of+Virus+Targeting+Peptides+for+Animal+Testing+in+the+Development+of+a+COVID-19+Vaccine/16782289.html

[mick]

$AIKI thank you , $HOTH ????? what they do ?????

[Viewmont]

Drug approvals could happen. Also HOTH is associated with AIKI.

[Viewmont]

Great job!

[Viewmont]

No, this wasn't the co.

[mick]

$AIKI,can you give information that you know will make $AIKI $5 or better ?????

[mick]

$AIKI reading , i got in this morning !!!!!

[mick]

$AIKI , i updated ibox some.

[mick]

$AIKI, is this company that has drug that w.h.o. said does not help any wit the coronavirus ?????

i ferget drug name !!!!!

trump was taking the drug and said no side effects ?????

news out friday drug does work & needs more theory !!!!!

[Viewmont]

Thanks mick!

[mick]

$AIKI, NICE REPORE' MY FRIEND !!!!!

[mick]

$AIKI NICE REVIEW DARE !!!!

[Viewmont]

It'll go insanely north when AIKI announces the right news!

[mick]

$AIKI i just started reading on $AIKI

[Viewmont]

Could be huge!

[mick]

$AIKI READING YOUR MESSAGE INTERESTING.
NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a

sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

Research will operate under the direction of Dr. Michael Peters to develop and optimize peptide biomimetics in order to achieve high binding rates of peptide to the RBD of SARS-Cov-2 spike protein at the

nanomolar level with demonstrated negligible toxicity through combined computational and experimental efforts.

Specifically, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides.

These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination,
binding to the spike protein, and finally cell challenge assays with SARS-Cov-2. Hoth Therapeutics has exclusive license to this novel peptide COVID-19 therapeutic.

"VCU, through the leadership of Dr. Michael Peters, has made significant strides in the research of the COVID-19 disease," said Mr. Robb Knie, CEO of Hoth Therapeutics.

"We look forward to working with VCU in accelerating progress on the development of this intellectual property and in establishing novel treatments to combat the pandemic."

Currently, Dr. Peters is utilizing supercomputers as part of the
COVID-19 High Performance Computing (HPC) Consortium through the
Extreme Science and Engineering Discovery Environment (XSEDE),
a virtual system that scientists can use to interactively share computing resources.

The consortium is a private-public partnership that includes the
White House Office of Science and Technology Policy and major tech corporations.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders.

Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19.

To learn more, please visit HTTP://www.hoththerapeutics.com.

[Viewmont]

http://schrts.co/fRWhyzJm

[Viewmont]

Yup! Waiting for the big news move!

[mick]

$AIKI
https://aikidopharma.com/
https://aikidopharma.com/about/
https://aikidopharma.com/portfolio/
https://aikidopharma.com/portfolio/aml-all/
https://aikidopharma.com/portfolio/pancreatic-cancer/
https://aikidopharma.com/scientific-advisory-board/
https://aikidopharma.com/published-papers/
https://ir.aikidopharma.com/

About
AIkido Pharma Inc. .
AIkido Pharma Inc. is a biotechnology development company with a diverse portfolio of early stage small-molecule anti-cancer therapeutics.

The AIkido Pharma Inc. platform contains patented technology from leading universities and researchers and we seek to develop our innovative drugs through strong partnership with world renowned institutions, such as The University of Texas and Wake Forest University.

Our diverse pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Our pancreatic treatment has shown positive preclinical results for inhibiting pancreatic tumor growth in clinically relevant transgenic mouse models.

The drug has also demonstrated the potential to overcome tumor cell resistance to current chemotherapeutic drugs. Our AML drug is a next generation targeted therapeutic designed to overcome multiple resistance mechanisms observed with the current standard of care. In addition, we are constantly seeking to grow our pipe to treat unmet medical needs in oncology.

[mick]

$AIKI Spherix Incorporated, a biotechnology company,
focuses on developing small-molecule anti-cancer therapeutics.

Its pipeline of therapeutics includes therapies for pancreatic cancer, acute myeloid leukemia, and acute lymphoblastic leukemia.

The company's platform consists of patented technology from leading universities and researchers and in the process of developing an

innovative therapeutic drug platform through partnerships with world renowned educational institutions, including The University of Texas at

Austin and Wake Forest University.

It has a scientific research agreement with The University of Texas Southwestern Medical Center to use machine learning to find genetic
markers in people that indicate an increased risk of developing
pancreatic cancer.

Spherix Incorporated was founded in 1967 and is based in New York, New York.

[mick]

$AIKI AIkido Pharma Inc. Announces Key Progress in Computational Approaches to Identify Virus Treatments, Including Coronavirus PR Newswire (US) - 7/9/2020 1:31:00 PM
AIkido Pharma Inc. Provides Update to Machine Learning Pancreatic Cancer Research PR Newswire (US) - 6/26/2020 10:30:00 AM

[mick]

$AIKI Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2020 9:55:07 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/19/2020 6:00:46 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 6/12/2020 3:21:30 PM

[mick]

$AIKI Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 6/8/2020 3:04:29 PM
AIkido Pharma Announces Publication of Results from Sponsored Research at Wake Forest University PR Newswire (US) - 5/28/2020 10:00:00 AM

[mick]

Alkido Pharma Inc (AIKI)
0.885 ? -0.0451 (-4.85%)
Volume: 5,970,365 @07/10/20 7:59:13 PM EDT
Bid Ask Day's Range
0.87 0.88 0.86 - 0.9544
AIKI Detailed Quote

[Viewmont]

Share Structure
Market Cap Market Cap
4,488,243
07/09/2020
Authorized Shares
200,000,000
03/02/2020
Outstanding Shares
4,825,549
03/02/2020
https://www.otcmarkets.com/stock/AIKI/security

[Viewmont]

Thanks! Good luck!

[stock1ace1]

Awesome dd bought some today

[Viewmont]

Voltron Therapeutics, Inc. And Hoth Therapeutics Initiates Animal Testing Of HaloVax Self-Assembling Vaccine For COVID-19
8:39 am ET July 8, 2020 (Benzinga) Hot Stories Print
Animal Trials to Assess the Effect of Novel Vaccine HaloVax™ Against COVID-19

NEW YORK, July 08, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. announced today it has initiated preclinical animal testing of the first construct of its HaloVax Self-Assembling Vaccine (SAV) against COVID-19. Voltron will take two different vaccines, with differing sets of targets into preclinical testing, in order to identify the best balance of immune responses for prevention of this pandemic pathogen. HaloVax is being developed in conjunction with Hoth Therapeutics, Inc. (NASDAQ:HOTH).

The vaccine is built on a base of a heat shock protein (HSP70) that activates the cellular portion of the immune system; this is different from most other vaccine efforts, which have used adjuvants such as alum. The second portion of the vaccine consists of peptides derived from the COVID-19 virus, which are bound to the heat shock protein via Avidin and Biotin. This enables rapid iteration and up-to-date data informed changes in the peptide sequences to enable swift production and accommodate potential changes in the pathogen itself. The selected immunogenic peptides complete the customized COVID-19 vaccine.

[Viewmont]

https://halovax.com/

[Viewmont]

https://voltrontx.com/ SPEX/HOTH/VOLTRON have been working together on cures.

[Viewmont]

https://hoththerapeutics.com/

[Viewmont]

https://aikidopharma.com/portfolio/pancreatic-cancer/

[Viewmont]

You welcome! Good luck!

[makingitnow]

Thanks for that response. I was trying to determine if it was bullish for the stock. we hit the 200 day Friday and was looking for something to be bullish about.

[Viewmont]

The Distribution

Distributing company AIkido Pharma Inc., a Delaware corporation (“AIkido”).

Distributed company Hoth Therapeutics, Inc., a Nevada corporation (“Hoth”).

Securities to be distributed 70,000 shares of Hoth common stock will be distributed to AIkido’s stockholders.

Reasons for the distribution Aikido’s management and board of directors periodically reviews and assesses strategic alternatives to ensure that all of its assets are being utilized in the best manner to create value for AIkido and its stockholders. Aikido’s management and board of directors has determined that the best strategy for realizing value for its shareholders is to distribute 70,000 shares of common stock of Hoth to its stockholders.

Distribution ratio and record date Each holder of AIkido common stock as of the close of business on , 2020, the record date for the distribution, will receive a dividend of share of Hoth common stock for each shares of AIkido common stock held by such holder.

Manner of effecting the distribution The distribution will consist of AIkido’s payment of a dividend to AIkido’s stockholders in the form of shares of Hoth common stock. No vote or approval of AIkido’s stockholders is required in connection with the distribution. You will not be required to make any payment, or to surrender or exchange your shares of AIkido’s common stock, or take any other action to receive your shares of our common stock, and Aikido’s stockholders will continue to own all shares of AIkido common stock held by them. If you own AIkido common stock as of the close of business on the record date, AIkido, with the assistance of Continental Stock Transfer & Trust Company (“Continental”), the distribution agent and Hoth’s transfer agent, will electronically issue shares of our common stock to you or to your brokerage firm on your behalf by way of direct registration in book-entry form. Continental will mail to you a book-entry account statement that reflects your shares of Hoth common stock, or your bank or brokerage firm will credit your account for the shares. If you sell shares of AIkido common stock in the market up to and including through the distribution date, you will be selling your right to receive shares of Hoth common stock in the distribution. Following the distribution, stockholders may request that their shares be transferred to a brokerage or other account at any time, without charge. Please see “The Distribution — Direct Registration System” section of this prospectus for a more detailed description of the direct registration system and how shares of Hoth common stock may be sold and transferred.

Expected distribution date On or about , 2020

Distribution agent, transfer agent and registrar for the shares Continental will be the distribution agent for the distribution and the transfer agent and registrar for Hoth common stock following the distribution.

United States federal income tax consequences of the distribution AIkido expects that the distribution will be treated as a taxable distribution in an amount equal to the fair market value of the Hoth shares on the distribution date. This amount will be treated as a dividend to the extent of any current or accumulated earnings and profits of AIkido, including any gain resulting from the distribution, with the excess treated as a non-taxable return of capital, to the extent of a holder’s tax basis in AIkido common stock and any remaining excess treated as capital gain. For a discussion of the tax consequences to AIkido and AIkido’s stockholders of the distribution, see the “Material United States Federal Income Tax Considerations” section of this prospectus. AIkido’s stockholders should consult with their own individual tax advisors regarding the tax consequences of the distribution.

Trading market Hoth’s shares of common stock are presently listed on The Nasdaq Capital Market under the symbol “HOTH.”

Relationship with AIkido after the distribution Immediately following the completion of the distribution, AIkido will own approximately % of our outstanding shares of common stock. We are a party to agreements with AIkido relating to its ownership of our common stock and other matters as described in the “Certain Relationships and Related Party Transactions” section of this prospectus.

Risk factors You should carefully consider the matters discussed in the “Risk Factors” section of this prospectus.

https://thefly.com/landingPageNews.php?id=3061607&headline=HOTH;AIKI-Hoth-Therapeutics-HaloVax-to-advance-application-of-VaxCelerate

[makingitnow]

How does this effect AIKI? I don't see our name mentioned.

[Viewmont]

NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

Research will operate under the direction of Dr. Michael Peters to develop and optimize peptide biomimetics in order to achieve high binding rates of peptide to the RBD of SARS-Cov-2 spike protein at the nanomolar level with demonstrated negligible toxicity through combined computational and experimental efforts. Specifically, point mutations will be conducted in-silico in order to seek to improve the stability and binding properties of these decoy peptides. These optimized, in-silico peptides will be synthesized and experimentally characterized through structure determination, binding to the spike protein, and finally cell challenge assays with SARS-Cov-2. Hoth Therapeutics has exclusive license to this novel peptide COVID-19 therapeutic.

"VCU, through the leadership of Dr. Michael Peters, has made significant strides in the research of the COVID-19 disease," said Mr. Robb Knie, CEO of Hoth Therapeutics. "We look forward to working with VCU in accelerating progress on the development of this intellectual property and in establishing novel treatments to combat the pandemic."

Currently, Dr. Peters is utilizing supercomputers as part of the COVID-19 High Performance Computing (HPC) Consortium through the Extreme Science and Engineering Discovery Environment (XSEDE), a virtual system that scientists can use to interactively share computing resources. The consortium is a private-public partnership that includes the White House Office of Science and Technology Policy and major tech corporations.

About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.

[Viewmont]

Hoth Therapeutics Announces Sponsored Research Agreement with VCU for Potential COVID-19 Treatment
Hoth has exclusive license to this novel peptide COVID-19 therapeutic
NEW YORK, June 30, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced entering into a sponsored research agreement with Virginia Commonwealth University (VCU) for a potential COVID-19 treatment.

[Viewmont]

Soon we shall see AIKI running!

[gaardo]

Cant stand that guy!